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jc.2011.0Abstract A series of 1-methyl-N-[(substituted-phenylmethylidene)-1H-benzimidazol-2-amines
(4a–4g) were prepared via the formation of 1-methyl-1H-benzimidazol-2-amine (3), which was pre-
pared by the cycloaddition of o-phenylenediamine (1) with cyanogen bromide in the presence of
aqueous base followed by N-methylation with methyl iodide in the presence of anhydrous potas-
sium carbonate in dry acetonitrile. Moreover, the four-membered b-lactam ring was introduced
by the cycloaddition of 4a–4g and chloroacetyl chloride in the presence of triethylamine catalyst
to give 3-chloro-1-(1-methyl-1H-benzimidazol-2-yl)-(40-substituted)-phenylazetidin-2-one 5a–5g. A
total of 14 compounds were synthesized and characterized by IR, 1H NMR, 13C NMR and Mass
spectral technique, in addition they were evaluated for anti-bacterial and cytotoxic properties.
Among the chemicals tested 4a, 4b, 5a, 5b, 5g exhibited good antibacterial activity and 5f, 5g shown
good cytotoxic activity in vitro.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Despite numerous attempts to search and develop new struc-
tural prototype as effective antimicrobials, benzimidazoles
still remain as potential class of compounds. Recently, the91 9417563874; fax: +91
.uk (M. Noolvi), hpatel_38@
Saud University.
g by Elsevier
ng by Elsevier B.V. on behalf of K
2.011chemistry and biological proﬁles of various pharmacophores
of N-1 substituted and 2-substituted benzimidazole deriva-
tives have been worked out (Ansari and Lal, 2008). Effect
of substituents on the benzimidazole ring exhibited correlated
structure–activity relationship (Powers et al., 2006). Incorpo-
ration of an imidazole nucleus, a biologically active pharma-
cophore, in the benzimidazole molecule has made it a
versatile heterocycle with wide spectrum of biological activity.
Moreover, benzimidazole derivatives are structural isosteres
of naturally occurring nucleotides, which allow them to inter-
act easily with the biophores (Starcevic et al., 2007). There-
fore, numerous biological activities of benzimidazoles
derivatives have been described; antimicrobial (Kus et al.,
2009), anticancer (Thimmegowda et al., 2008), anti inﬂamma-
tory (Mader et al., 2008), antiviral (Vazquez et al., 2001),ing Saud University.
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mez et al., 2008), antihelminitics (Dahiya and Pathak,
2007), protein kinase inhibitors (Bernatowicz et al., 2009)
and H+/K+ ATPase inhibitors (Cho et al., 2001). Polyfunc-
tionality of 2-aminobenzimidazole molecule resulting from
the cyclic guanidine moiety has made it a building block
for the synthesis of a large number of derivatives of pharma-
cological interest (Mavrova et al., 2007). Different substituted
2-aminobenzimidazoles have been found to possess in vivo
and in vitro growth inhibition activity against various strains
of bacteria, fungi and yeast.
On the other side, literature survey revealed that 2-azetidi-
nones are associated with various pharmacological activities.
A large number of 3-chloro monocyclic b-lactam having sub-
stitution at positions 1 and 4 possess powerful anti-bacterial,
anti-microbial, sedative, anti-fungal and anti-tubercular activ-
ity (Kagan and Luche, 1968; Mohamed et al., 2006). With the
above facts and in continuation of our research for newer
anti-cancer and anti-microbial agents in the present study,
we report here the synthesis of 2-azetidinone derivatives of
2-amino-1H-benzimidazoles to develop potential drug candi-
dates of this class (Manjula et al., 2009; Badiger et al., 2006).
These molecules operate by forming a covalent adduct with
the membrane-bound bacterial transpeptidase, also known as
penicillin binding proteins (PBPs), involved in the biosynthesis
of cell walls. These mechanism-based inhibitors prevent the
construction of cell wall and eventually lead to cell lysis and
death (Halve et al., 2007).2. Material and method
2.1. Chemistry
All chemicals and solvents were supplied by Merck, S.D.
Fine-chem limited, Mumbai. All the solvents were distilled
and dried before use. The reactions were monitored with
the help of thin-layer chromatography using pre-coated alu-
minum sheets with GF254 silica gel, 0.2 mm layer thickness
(E. Merck). Various solvent systems used for developing the
chromatograms were (a) chloroform/methanol (9:1), (b) chlo-
roform/methanol (9.5:0.5), (c) ethyl acetate/pet-ether (2:1)
and (d) chloroform/benzene (1:1). Columns of different sizes
packed with G60 (70–230 mesh) silica gel was used for puri-
ﬁcation. Melting points of the synthesized compounds were
recorded on the Veego (VMP-MP) melting point apparatus.
IR spectrum was acquired on a Shimadzu Infra Red Spec-
trometer, (model FTIR-8400S). 1H NMR spectra of the syn-
thesized compounds were performed in DMSO with a Bruker
Avance-II 400 NMR Spectrometer operating at 400 MHz in
SAIF, Punjab University (Chandigarh). 13C NMR spectra
of the synthesized compounds were scanned with a Bruker
Avance-II 400 NMR Spectrometer operating at 400 MHz in
Regional Research Laboratory (RRL), Jammu Tawi. Chem-
ical shifts are reported in d scale (ppm). Mass spectra of
the synthesized compounds were recorded at MAT 120 in
SAIF, Punjab University, Chandigarh and Regional Research
Laboratory (RRL), Jammu Tawi.
2.1.1. Synthesis of 2-aminobenzimidazoles (2)
o-Phenylenediamine 1 (43.2 g, 0.4 mol) was stirred with water
(400 mL) in an ice-bath and cyanogen bromide (35.5 g,0.333 mol) was added drop wise during 1 h. The mixture was
stirred for 3 h, ﬁltered, and made basic with aqueous sodium
hydroxide, the base being precipitated and ﬁltered off. The so-
lid obtained was ﬁltered, and crystallized from water to give 2,
yield 70.1%, mp 226–228 C, kmax (methanol) 212 nm; IR
(KBr, m, cm1): 3383 and 3060 (–NH, –NH2), 1168 and 1568
(NH bend), 1269 and 1313 (–C–N); 1H NMR (400 MHz,
DMSO-d6) d (ppm): 5.6 (s, 2H, NH2), 6.7 (s, 1H, NH), 7.10–
7.28 (m, 4H, Ar-H); 13CNMR (400 MHz, DMSO-d6) d
(ppm): Benzimidazole C: [154.63 (C), 138.48 (C), 134.89 (C),
122.67 (CH), 116.29 (CH), 118.54 (CH)]; HRMS calcd for
C3H7N3: 133.1511, found 133.1592.
2.1.2. Synthesis of 1-methyl-1H-benzimidazol-2-amine (3)
Compound 2 (2.6 g, 0.02 mol) and potassium carbonate (2.6 g,
0.02 mol), acetonitrile (30 mL) methyl iodide (0.75 mL,
0.01 mol) were reﬂuxed under nitrogen overnight at 50 C then
added water and extracted with ethyl acetate. Dried with
MgSO4 and recrystallized from ethanol to give compound 3,
yield 78%, mp 201–203 C (in water), 209–210 C (in acetone),
kmax (methanol) 211 nm; IR (KBr, m, cm
1): 3374 (–NH, –
NH2), 2921 and 2849 (C–CH3), 1314 and 1270 (C–N);
1H
NMR (400 MHz, DMSO-d6) d (ppm): 3.9 (s, 2H, NH2), 3.5
(s, 3H, CH3), 7.20–7.48 (m, 4H, Ar-H);
13CNMR (400 MHz,
DMSO-d6) d (ppm): Benzimidazole C: [153.67 (C), 139.47
(C), 132.27 (C), 121.34 (CH), 116.29 (CH), 111.25 (CH)],
27.89 (N–CH3); HRMS calcd for C8H9N3: 147.1771, found
147.1751
2.1.3. General procedure for the synthesis of compounds (4a–4g)
The 2-amino-1-methyl benzimidazole 3 (0.01 mol) was added
to a solution of the different substituted benzaldehydes
(0.012 mol) in dry ethanol 40 mL in RBF. Dry benzene
(10 mL) and two drops of glacial acetic acid were also added
to the above mixture. The mixture was reﬂuxed for 8–20 h
and at the end of the reaction; solvents were partially evapo-
rated then poured into water. The precipitates were collected
by ﬁltration, washed with ether, dried and compounds 4a–4g
were synthesized and recrystallized from the appropriate sol-
vent like ethanol or ethanol–water.
2.1.3.1. N-[(4-Chlorophenyl) methylidene]-1-methyl-1H-ben-
zimidazol-2-amine (4a). This was prepared and puriﬁed as per
the above mentioned procedure: yield 58%, mp 216–218 C,
kmax (methanol) 208.4 nm; IR (KBr, m, cm
1): 1432 (–N‚CH),
1092 (Ar-Cl), 2925 and 2869 (N–CH3);
1H NMR (400 MHz,
DMSO-d6) d (ppm): 2.46 (s, 3H, N–CH3), 7.35–7.82 (4H,
Ar-H), 7.11–7.30 (m, 4H, Ar-H), 9.3 (s, 1H, N‚CH);
13CNMR (400 MHz, DMSO-d6) d (ppm): Benzimidazole C:
[151.14 (C), 140.47 (C), 134.2 (C), 120.98 (CH), 114.25 (CH),
111.25 (CH)], Arom-C: [135.66 (C), 133.57 (C), 131.67 (CH),
130.76 (CH)], 156.67 (N‚CH), 26.18 (N–CH3); HRMS calcd
for C15H12ClN3: 269.7291, found 269.7234.
2.1.3.2. 1-Methyl-N-[(4-nitrophenyl) methylidene]-1H-ben-
zimidazol-2-amine (4b). This was prepared and puriﬁed as per
the above mentioned procedure: yield 58.9%, mp 248–250 C,
kmax (methanol) 208.5 nm; IR (KBr, m, cm
1): 1432 (N‚CH),
1515 (–N‚O), 1342 (–N‚O), 855 and 834 (–C–NO), 2929 and
2849 (N–CH3);
1H NMR (400 MHz, DMSO-d6) d (ppm): 2.42
(s, 3H, –N–CH3), 7.62–8.34 (4H, Ar-H), 7.14–7.43 (m, 4H, Ar-
H), 9.53 (s, 1H, –N‚CH); 13C NMR (400 MHz, DMSO-d6) d
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120.76 (CH), 116.24 (CH), 110.78 (CH)], Arom-C: [136.2
(C), 131.57 (C), 126.88 (CH), 124.98 (CH)], 156.15 (N‚CH),
26.87 (N–CH3); HRMS calcd for C15H12N4O2: 280.2831,
found 280.2842.
2.1.3.3. 1-Methyl-N-[(2-nitrophenyl) methylidene]-1H-ben-
zimidazol-2-amine (4c). This was prepared and puriﬁed as
per the above mentioned procedure: yield 61.4%, mp 149–
151 C, kmax (methanol) 252 nm; IR (KBr, m, cm1): 1429
(–N‚CH), 1519 (–N‚O), 1342 (–N‚O), 854 (–C–NO),
2831 and 2881 (–N–CH3);
1H NMR (400 MHz, DMSO-d6) d
(ppm): 2.40 (s, 3H, N–CH3), 7.12–8.30 (m, 8H, Ar-H), 9.54
(s, 1H, –N‚CH); 13C NMR (400 MHz, DMSO-d6) d (ppm):
Benzimidazole C: [151.76 (C), 140.46 (C), 136.23 (C), 120.80
(CH), 114.21 (CH), 110.78 (CH)], Arom-C: [135.81 (C),
130.41 (C), 133.98 (CH), 130.93 (CH), 128.17 (CH), 124.32
(CH)], 156.74 (N‚CH), 26.24 (N–CH3); HRMS calcd for
C15H12N4O2: 280.2821, found 280.2823.
2.1.3.4. 1-Methyl-N-[(3-nitrophenyl) methylidene]-1H-ben-
zimidazol-2-amine (4d). This was prepared and puriﬁed as
per the above mentioned procedure: yield 62.5%, mp 180–
182 C, kmax (methanol) 209.2 nm; IR (KBr, m, cm1): 1427
(–N‚CH), 1518 (N‚O), 1342 (–N‚O), 846 (–C–NO), 2935
and 2850 (–N–CH3);
1H NMR (DMSO): 2.44 (s, 3H, –N–
CH3), 7.20–7.40 (m, 4H, Ar-H), 7.82–8.24 (m, 3H, Ar-H),
9.20 (s, 1H, –N‚CH); 13C NMR (400 MHz, DMSO-d6) d
(ppm): Benzimidazole C: [151.56 (C), 139.49 (C), 133.27 (C),
120.98 (CH), 118.21 (CH), 110.78 (CH)], Arom-C: [132.45.0
(C), 131.18 (C), 129.78 (CH), 128.67 (CH), 126.72 (CH),
124.96 (CH)], 158.89.0 (N‚CH), 26.23 (N–CH3); HRMS
calcd for C15H12N4O2: 280.2812, found 280.2818.
2.1.3.5. N-{[4-(Dimethylamino) phenyl] methylidene}-1-
methyl-1H-benzimidazol-2-amine (4e). This was prepared and
puriﬁed as per the above mentioned procedure: yield 51%,
mp 120–124 C, kmax (methanol) 343 nm; IR (KBr, m, cm1):
1440 (–N‚CH), 2949 and 2834 (–N–CH3);
1H NMR
(400 MHz, DMSO-d6) d (ppm): 2.35 (s, 3H, N–CH3), 2.90 (s,
6H, N(CH3)2, 7.10–7.56 (m, 8H, Ar-H), 9.34 (s, 1H, N‚CH);
13C NMR (400 MHz, DMSO-d6) d (ppm): Benzimidazole C:
[151.78 (C), 139.4 (C), 132.2 (C), 120.89 (CH), 118.21 (CH),
110.78 (CH)], Arom-C: [131.64 (C), 125.99 (C), 127.37 (CH),
110.19 (CH)], 158.89.0 (N‚CH), 26.34 (N–CH3), 40.34 [N–
(CH3)2]; HRMS calcd for C17H18N4: 278.3522, found
278.3541.
2.1.3.6. N-[(2,5-Dimethoxyphenyl) methylidene]-1-methyl-1H-
benzimidazol-2-amine (4f). This was prepared and puriﬁed as
per the above mentioned procedure: yield 53.5%, mp
157–159 C, kmax (methanol) 343 nm; IR (KBr, m, cm1):
1440 (–N‚CH), 2904 and 2820 (–N–CH3);
1H NMR
(400 MHz, DMSO-d6) d (ppm): 2.40 (s, 3H, N–CH3), 3.48 (s,
3H, OCH3), 3.58 (s, 3H, OCH3), 7.12–7.45 (m, 4H, Ar-H),
7.51 (m, 2H, Ar-H), 7.67 (s, 1H, Ar-H), 9.38 (s, 1H, N‚CH);
13CNMR (400 MHz, DMSO-d6) d (ppm): Benzimidazole C:
[151.16 (C), 138.42 (C), 136.25 (C), 120.76 (CH), 115.23
(CH), 110.89 (CH)], Arom-C: [134.23 (C), 132.49 (C), 130.71
(C), 117.63 (CH), 115.34 (CH), 112.14 (CH)], 158.34 (N‚CH),
26.89 (N–CH3), 45.8 (OCH3); HRMS calcd for C17H17N3O2:
295.3362, found 295.3321.2.1.3.7. N-[(2-Chlorophenyl) methylidene]-1-methyl-1H-ben-
zimidazol-2-amine (4g). This was prepared and puriﬁed as per
the above mentioned procedure: yield 55.5%, mp 235–237 C,
kmax (methanol) 252.6 nm; IR (KBr, m, cm
1): 1430 (–N‚CH),
1091 and 822 (Ar-Cl), 2925 and 2868 (N–CH3);
1H NMR
(400 MHz, DMSO-d6) d (ppm): 2.40 (s, 3H, N–CH3), 7.15–
7.80 (m, 8H, Ar-H), 9.58 (s, 1H, N‚CH); 13CNMR
(400 MHz, DMSO-d6) d (ppm): Benzimidazole C: [151.21
(C), 141.54 (C), 132.62 (C), 120.23 (CH), 114.2 (CH), 110.34
(CH)], Arom-C: [132.91 (C), 131.41 (C), 130.43 (CH), 128.31
(CH), 126.24 (CH), 122.98 (CH)], 158.12 (N‚CH), 26.98
(N–CH3); HRMS calcd for C15H12ClN3Cl2: 269.2791, found
269.2762.
2.1.4. General procedure for the synthesis of compounds (5a–5g)
Schiff bases 4a–4g, (0.04 mol) and triethylamine (0.02 mol) in
dioxan (20 mL) at 0–5 C mixture was stirred for 5 h. During
stirring, chloroacetyl chloride (0.01 mol) in dioxan (10 mL)
was added dropwise. The mixture was reﬂuxed for 2 h and
kept for two days on room temperature. The resulting mixture
was poured in the water and the solid was separated out.
Recrystallization was done with ethanol–water or chloro-
form–water to give the azetidine-2-one, 5a–5g compounds.
2.1.4.1. 3-Chloro-4-(4-chlorophenyl)-1-(1-methyl-1H-ben-
zimidazol-2-yl) azetidin-2-one (5a). This was prepared and
puriﬁed as per the above mentioned procedure: yield 47.7%,
mp 160–162 C, kmax (methanol) 203.8 nm; IR (KBr, m, cm
1): 2925 and 2852 (N–CH3), 1685 (C‚O), 813 and 741 (Cl–
C), 1094 (Ar-Cl); 1H NMR (400 MHz, DMSO-d6) d (ppm):
1.12 (s, 1H, –CH), 2.43 (s, 3H, N–CH3), 6.72 (s, 1H, –CH),
7.14–7.34 (m, 4H, Ar-H), 7.41–8.47 (4H, Ar-H); 13C NMR
(400 MHz, DMSO-d6) d (ppm): Benzimidazole C: [155.93
(C), 137.21 (C), 135.16 (C), 123.41 (CH), 116.23 (CH),
111.45 (CH)], Arom-C: [140.18 (C), 130.13 (C), 126.35 (CH),
125.48 (CH)], 29.45 (N–CH3), b-lactam C: [164.42 (C‚O),
62.53 (CHCl), 64.61 (CH)]; LC–MS m/z (% RA):
M+1= 347.3 (35%), 331.3 (55%), 305.2 (33%), 274.0
(25%), 174.2 (87%), 122.0 (19%), 106.0 (45%), 104.0 (100%)
and HRMS calcd for C17H13ON3Cl2: 346.2106, found
346.2112.
2.1.4.2. 3-Chloro-1-(1-methyl-1H-benzimidazol-2-yl)-4-(4-
nitrophenyl) azetidin-2-one (5b). This was prepared and puri-
ﬁed as per the above mentioned procedure: yield 51.96%,
mp 195–197 C, kmax (methanol) 204 nm; IR (KBr, m, cm1):
1682 (–C‚O), 2921 and 2849 (–N–CH3), 1520 (–N‚O),
1344 (–N‚O), 864 and 816 (–C–NO); 1H NMR (400 MHz,
DMSO-d6) d (ppm): 1.11 (s, 1H, –CH), 2.48 (s, 3H, N–CH3),
6.75 (s, 1H, –CH), 7.10–8.47 (2H, Ar-H); 7.10–7.28 (m, 4H,
Ar-H), 7.42–8.49 (4H, Ar-H); 13C NMR (400 MHz, DMSO-
d6) d (ppm): Benzimidazole C: [155.78 (C), 136.43 (C), 132.65
(C), 123.63 (CH), 114.62 (CH), 112.16 (CH)], Arom-C:
[148.71 (C), 146.79 (C), 122.14 (CH), 122.23 (CH)], 29.64
(N–CH3), b-lactam C: [164.55 (C‚O), 62.31 (CHCl), 63.35
(CH)]; LC–MS m/z (% RA): M+NH3 = 373.2 (41%), 353.3
(30%), 331.3 (54%), 284.4 (22%), 174.2 (25%), 158.1 (14%),
102.1 (100%) and HRMS calcd for C17H13O3N4Cl: 356.7631,
found 356.7625.
2.1.4.3. 3-Chloro-1-(1-methyl-1H-benzimidazol-2-yl)-4-(2-nitro-
phenyl) azetidin-2-one (5c). This was prepared and puriﬁed as
222 M. Noolvi et al.per the above mentioned procedure: yield%, mp 168–170 C,
kmax (methanol) 248.6 nm; IR (KBr, m, cm
1): 1682 (–C‚O),
2921 and 2849 (N–CH3), 1520 and 1344 (–N‚O), 864 and
816 (C–NO); 1H NMR (400 MHz, DMSO-d6) d (ppm): 1.17
(s, 1H, –CH), 2.41 (s, 3H, N–CH3), 6.67 (s, 1H, –CH), 7.13–
8.22 (m, 8H, Ar-H); 13C NMR (400 MHz, DMSO-d6) d
(ppm): Benzimidazole C: [154.12 (C), 136.43 (C), 134.21 (C),
123.12 (CH), 116.51 (CH), 110.12 (CH)], Arom-C: [146.21
(C), 136.15 (C), 134.16 (CH), 126.48 (CH), 125.37 (CH),
124.46 (CH)], 29.36 (N–CH3), b-lactam C: [167.24 (C‚O),
62.12 (CHCl), 63.15(CH)]; DIPMS m/z: 356.76 M+ and
HRMS calcd for C17H13O3N4Cl: 356.7631, found 356.7627.
2.1.4.4. 3-Chloro-1-(1-methyl-1H-benzimidazol-2-yl)-4-(3-nitro-
phenyl) azetidin-2-one (5d). This was prepared and puriﬁed as
per the above mentioned procedure: yield 49.7%, mp
132–134 C, kmax (methanol) 204.6 nm; IR (KBr, m, cm1):
1677(–C‚O), 2953 and 2874 (–N–CH3), 1536 (–N‚O), 1347
(–N‚O), 810 (–C–NO); 1H NMR (400 MHz, DMSO-d6) d
(ppm): 1.15 (s, 1H, –CH), 2.44 (s, 3H, N–CH3), 6.63 (s, 1H,
–CH), 7.18–7.78 (m, 4H, Ar-H), 7.84–8.43 (m, 3H, Ar-H),
8.82 (s, 1H, Ar-H);13C NMR (400 MHz, DMSO-d6) d (ppm):
Benzimidazole C: [155.18 (C), 137.24 (C), 135.25 (C), 123.45
(CH), 112.15 (CH), 111.24 (CH)], Arom-C: [145.57 (C),
138.45 (C), 130.30 (CH), 129.34 (CH), 121.49 (CH), 118.55
(CH)], 29.12 (N–CH3), b-lactam C: [167.52 (C‚O), 62.12
(CHCl), 63.14 (CH)]; DIPMS m/z: 356.76 M+ and HRMS
calcd for C17H13O3N4Cl: 356.7631, found 356.7630.
2.1.4.5. 3-Chloro-4-[4-(dimethylamino) phenyl]-1-(1-methyl-
1H-benzimidazol-2-yl) azetidin-2-one (5e). This was prepared
and puriﬁed as per the above mentioned procedure: yield
44.5%, mp 114–116 C, kmax (methanol) 239.5 nm; IR (KBr,
m, cm1): 1677 (–C‚O), 2955 and 2839 (–N–CH3);
1H NMR
(400 MHz, DMSO-d6) d (ppm): 1.21 (s, 1H, –CH), 2.46 (s,
3H, N–CH3), 6.62 (s, 1H, –CH), 7.10–7.56 (m, 8H, Ar-H);
13C NMR (400 MHz, DMSO-d6) d (ppm): Benzimidazole C:
[155.18 (C), 136.23 (C), 135.25 (C), 121.33 (CH), 115.53
(CH), 111.45 (CH)], Arom-C: [146.51 (C), 130.67 (C), 128.21
(CH), 112.17 (CH)], 29.13 (N–CH3), b-lactam C: [169.12
(C‚O), 62.12 (CHCl), 63.11 (CH)], 35.31 [N(CH3)2]; LC–
MS m/z (% RA): M+2= 352.8 (58%), 318.7 (32%), 286.7
(13%), 262.8 (22%), 171.8 (45%), 128.8 (38%), 103.3 (100%)
and HRMS calcd for C19H19ON4Cl: 354.8334, found
354.8330.
2.1.4.6. 3-Chloro-4-(2,5-dimethoxyphenyl)-1-(1-methyl-1H-
benzimidazol-2-yl) azetidin-2-one (5f). This was prepared
and puriﬁed as per the above mentioned procedure: yield
50.23%, mp 158–160 C, kmax (methanol) 240.7 nm; IR
(KBr, m, cm1): 1677 (C‚O), 2955 and 2839 (N–CH3);
1H
NMR (400 MHz, DMSO-d6) d (ppm): 1.17 (s, 1H, –CH),
2.48 (s, 3H, N–CH3), 6.63 (s, 1H, –CH), 7.06–7.42 (m, 4H,
Ar-H), 7.55 (m, 2H, Ar-H), 7.78 (s, 1H, Ar-H); 13C NMR
(400 MHz, DMSO-d6) d (ppm): Benzimidazole C: [146.23
(C), 136.24 (C), 132.12 (C), 122.34 (CH), 115.56 (CH),
113.12 (CH)], Arom-C: [145.76 (C), 143.48 (C), 128.45 (C),
116.31 (CH), 115.67 (CH), 113.19 (CH)], 29.59 (N–CH3), b-
lactam C: [168.65 (C‚O), 62.53 (CHCl), 64.23 (CH) ], 51.95
(OCH3), 51.41 (OCH3); DIPMS m/z: 371.10 M
+ and HRMS
calcd for C19H18O3N3Cl: 371.1037, found 371.1035.2.1.4.7. 3-Chloro-4-(2-chlorophenyl)-1-(1-methyl-1H-ben-
zimidazol-2-yl) azetidin-2-one (5g). This was prepared and
puriﬁed as per the above mentioned procedure: yield 53.5%,
mp 130–132 C, kmax (methanol) 248.6 nm; IR (KBr, m, cm
1): 2923, 2848 (N–CH3), 1684 (–C‚O), 812 and 741 (Cl–C–
); 1H NMR (400 MHz, DMSO-d6) d (ppm): 1.25 (s, 1H,
–CH), 2.53 (s, 3H, N–CH3), 6.72 (s, 1H, –CH), 7.23–7.92 (m,
8H, Ar-H); 13C NMR (400 MHz, DMSO-d6) d (ppm): Benz-
imidazole C: [154.89 (C), 136.26 (C), 134.27 (C), 123.45
(CH), 116.25 (CH), 111.23 (CH)], Arom-C: [140.45 (C),
134.52 (C), 130.65 (CH), 128.53 (CH), 128.14 (CH), 125.63
(CH)], 29.78 (N–CH3), b-lactam C: [167.42 (C‚O), 62.18
(CHCl), 64.32 (CH)]; DIPMS m/z: 346.21 M+ and HRMS
calcd for C17H13ON3Cl2: 346.2106, found 346.2114.
2.2. Antimicrobial activity
2.2.1. Sample preparation
Each of the test compounds and standard ampicillin was dis-
solved in DMSO, at concentrations of 1000 lg/mL. Further
dilutions of the compounds and standards in the test medium
were prepared at the required quantities of 400, 200, 100, 50,
25, 12.5 and 6.5 lg/mL.
2.2.2. Culture of microorganisms
Four strains of bacteria were used as test microorganisms. The
bacterial strains included Gram-positive Staphylococcus aureus
(ATCC 6538), Bacillus pumilus (ATCC 14884) and Gram-neg-
ative Escherichia coli (NCTC 10418), Pseudomonas aeruginosa
(ATCC 25619). All microorganisms were obtained from the
microbiological section of Shree Dhanvantary Pharmaceutical
Analysis and Research Centre (SDPARC), Kim (Surat). The
cultures were carefully identiﬁed as authentic using standard
microbiological methods.
2.2.3. Assay for in vitro antimicrobial activity
The in vitro antimicrobial activity of compounds was tested
by agar diffusion assay (Ella et al., 1996; Katritzky and
Rachal, 1994). The agar diffusion assay was followed to
determine the minimum inhibitory concentration (MIC) of
all the synthesized compounds. Nutrient agar was employed
as a culture medium for antibacterial activity. The sterilized
(autoclaved at 120 C for 30 min) medium at 40–50 C was
inoculated with (0.001 mL/mL of medium) of suspension
of microorganism and poured into a petri dish to give a
depth of 3–4 mm and was allowed to solidify (Fioravanti
et al., 1995). Bores were made on the medium using a sterile
borer. Test solution (0.1 mL) and standard solution (100 lg/
mL in dimethyl sulfoxide) were taken. The plates were incu-
bated at 37 C for 24 h. Following which the zone of inhibi-
tion was measured, to compare the potency of test with that
of standard. The minimal inhibitory concentrations (MIC)
of the compounds were determined by the agar diffusion
assay.
2.3. In vitro cytotoxic activities (MTT assay)
In vitro cytotoxicity was determined using a standard MTT as-
say with protocol appropriate for the individual test system
(Abdel-Hafez, 2007). In brief, exponentially growing cells were
plated in 96-well plates (104 cells/well in 100 lL of medium)
Scheme 1 Reactants: (a) CNBr, THF, aq. NaOH; (b) CH3I,
K2CO3, acetonitrile; (c) C2H5OH, substituted aldehydes,
CH3COOH; (d) ClCH2COCl, N(C2H5)3, dioxane.
Synthesis, antimicrobial and cytotoxic activity of novel azetidine-2-one derivatives of 1H-benzimidazole 223and incubated for 24 h. Test compounds were prepared prior
to the experiment by dissolving in 0.1% DMSO and were di-
luted with the medium. The cells were then exposed to different
concentrations of the drugs (1–100 lM) at a volume of 100 lL/
well. Cells in the control wells received the same volume of
medium containing 0.1% DMSO. After 24 h, the medium
was removed and the cell cultures were incubated with
100 lL MTT reagent (1 mg/mL) for 4 h at 37 C. The forma-
zan crystals produced by the viable cells were solubilized by
the addition of 100 lL DMSO. The suspension was placed
on micro-vibrator for 5 min and the absorbance was recorded
at 540 nm by the ELISA reader. The experiment was per-
formed in triplicate. The percentage cytotoxicity was calcu-
lated using the formula
%Cytotoxicity¼ ðControl absBlank absÞ ðTest absBlank absÞðControl absBlank absÞ  100
For MTT time course study, MCF-7 cells (5 · 103 cells/well)
seeded in 96-well plates were exposed to different concentra-
tions of test compounds (1–50 lM). The percentage cytotoxic-ity and IC50 values were determined at 24, 48 and 72 h of drug
incubation.
3. Result and discussion
In the present work, benzimidazole derivatives containing
azetidine-2-one moiety were prepared according to reaction
Scheme 1. 2-Amino-1H-benzimidazole (2) was prepared by
the cycloaddition of o-phenylenediamine 1 with cyanogen bro-
mide in presence of aqueous base.
The IR spectra of compound 2 shown two sharp absorp-
tion bands, one of which, appearing at 3383 cm1, was attrib-
uted to the NH function of 2-aminobenzimidazoles and other,
observed 3060 cm1, was assigned to NH2 stretching fre-
quency. The 1H NMR spectrum of compound 2 exhibited
two different signals at 5.6 ppm (NH2) and 6.7 ppm (NH)
integrating for 2 and 1 proton, respectively. The signals of
aromatic carbon atom of compound were observed at
116.29–154.63 ppm.
2-Amino-1H-benzimidazole 2 on N-methylation with
methyl iodide in the presence of anhydrous potassium car-
bonate in dry acetonitrile gave 1-methyl-1H-benzimidazole-
2-amine (3) which on condensation with various selected
aromatic aldehydes in the presence of benzene, ethanol and
few drops of acetic acid formed Schiff bases, (1-methyl-N-
[(substituted) phenylmethylidene]-1H-benzimidazol-2-amine
(4a–4g)).
The spectral data of 4a–4g shown IR band at 1432 cm1
conﬁrming the formation of imine (HC‚N–). Further 1H
NMR of compounds 4a–4g shown the presence of a singlet be-
tween d 8.90–9.54 ppm indicating the formation of imine
(>HC‚N–). A Peak at d 2.40–2.45 ppm shown the presence
of >N–CH3, d 7.10–8.30 ppm shown the presence of aromatic
protons. Syntheses of the compounds 3a–3g were also con-
ﬁrmed by 13C NMR data, peaks at d 26.23 ppm and
158.89 ppm have conﬁrmed the formation of methyl carbon
(N–CH3) and imine (>HC‚N–), respectively.
The four-membered b-lactam ring was introduced by the
cycloaddition of 4a–4g and chloroacetyl chloride in the pres-
ence of triethylamine catalyst to give 3-chloro-1-(1-methyl-
1H-benzimidazol-2-yl)-(40-substituted)-phenylazetidin-2-one
5a–5g.
Title compounds 5a–5g shown IR bands at 1677–1685 cm1
which conﬁrmed the formation of azetidine-2-one ring which
was further substantiated with the help of 1H NMR data with
the peaks at 1.17–1.26 ppm and d 6.65–6.67 ppm for the pro-
tons of lactam ring. It is further conﬁrmed by the absence of
peak at d 8.90–9.54 ppm for –CH‚N–. A peak was observed
for d 2.45 ppm for N–CH3 group, peaks between d 7.20–
8.70 ppm for respective aromatic protons. Synthesis of ﬁnal
compounds was also conﬁrmed by 13C NMR data, peaks be-
tween d 165–169 ppm, d 63.52 ppm and 61.23 ppm have con-
ﬁrmed the formation of lactam ring. Peaks between d 115–
150 ppm and d 29.3 conﬁrmed the presence of aromatic car-
bons and methyl carbon, respectively. Title compounds were
further conﬁrmed by mass spectral data, molecular ion M+
peak observed for compounds 5a–5g were m/z 344.5, 355.5,
355.76, 345.5, 353.83, 370.81, 355.76 and HRMS data.
The synthesized compounds 4a–4g, 5a–5g were screened for
their in vitro antimicrobial activity against Gram +ve bacteria
(Staphylococcus aureus, Bacillus pumillus) and Gram ve bac-
Table 4 The in vitro cytotoxic activity of compounds (5a–5g)
by MTT assay (MCF-7).
Compound IC50
a value (lM)
4a 13.0
4b 11.5
4f 6.0
4g 11.0
Cyclophosphamide 8.7
a IC50: the concentration that causes a 50% reduction of the cell
growth.
Table 1 In vitro antimicrobial activity of the synthetic compounds 4a–4g, 5a–5g at a concentration of 100 lg/mL (zone of inhibition
in mm) and minimum inhibitory concentration (MIC).
Compound R Zone of Inhibition in mm Minimum Inhibitory Concentration (lg/mL)
S. aureus B. pumillus E. coli P. aeruginosa S. aureus B. pumillus E. coli P. aeruginosa
3a 40-Chloro 12.4 10.2 11.9 10.6 50 75 50 50
3b 40-Nitro 12.9 11.3 11.8 10.8 50 75 50 50
3c 20-Nitro 11.8 11.5 NA 11.3 25 50 50 75
3d 30-Nitro 12.2 10.8 12.6 10.5 75 50 50 50
3e 40-Dimethylamin 11.3 10.2 10.8 10.6 50 75 75 50
3f 2,5-Dimethoxy 10.9 10.5 11.2 11.0 75 75 50 50
3g 20-Chloro 12.6 11.4 12.2 11.3 25 50 50 75
4a 40-Chloro 13.2 11.2 13.6 10.9 25 50 50 50
4b 40-Nitro 13.6 12.4 14.4 11.7 25 25 50 50
4c 20-Nitro 12.9 11.8 12.3 12.2 50 75 50 50
4d 30-Nitro 12.2 11.4 11.7 NA 50 50 75 75
4e 40-Dimethylamino 11.6 11.4 12.2 NA 50 50 50 50
4f 2,50-Dimethoxy NA 10.6 12.5 11.4 50 75 50 50
4g 20-Chloro 13.2 11.5 12.8 11.3 25 25 50 75
Std. Ampicillin 14.8 12.8 15.2 13.4 6.5 12.5 25 25
NA means no activity.
224 M. Noolvi et al.teria (Pseudomonas aeruginosa, Escherichia coli) by measuring
the zone of inhibition at concentration 100 lg/mL (mm), min-
imum inhibitory concentration (lg/mL) and % inhibition
shown in Table 1, respectively. Compounds 4a (12.4, 10.2,
11.9 and 10.8 mm), 4b (12.9, 11.3, 11.8 and 10.8 mm), 5a
(13.2, 11.2, 13.6, 11.4 mm), 5b (13.6, 12.4, 13.4 and 11.7 mm)
and 5g (13.2, 11.5, 12.8, 11.3 mm) against S. aureus, Bacillus
pumillus, E. coli and Pseudomonas aeruginosa compared with
the standard Ampicillin (13.8, 11.8, 13.2 and 12.4 mm) shown
good antimicrobial activities, respectively. Compounds 4g, 5a,
5b and 5g shown 25 lg/mL MIC against S. aureus and com-
pounds 5b and 5g also shown 25 lg/mL MIC against Bacillus
pumillus compared with standard Ampicillin (6.5, 12.5, 22,
25 lg/mL) against S. aureus, Bacillus pumillus, E. coli and
Pseudomonas aeruginosa, respectively. %Inhibition calculated
based on zone of inhibition, compound 5b shown maximum
% inhibition (52.78%) compared with standard Ampicillin
55.26% against Escherichia coli shown in Table 1.Table 2 In vitro % viability of compounds (5a–5g) by MTT
assay.
Conc. (lM) 5a 5b 5f 5g Cyclophosphamide
5.0 83.1 76.2 51.3 57.8 81.7
10.0 55.5 52.9 40.2 51.6 44.1
20.0 43.1 38.5 35.5 37 40.4
40.0 26.7 22.1 23.5 30.8 35.4
Table 3 In vitro % inhibitions of compounds (5a–5g) by
MTT assay (MCF-7).
Conc. (lM) 5a 5b 5f 5g Cyclophosphamide
5.0 16.9 23.8 48.7 42.2 18.3
10.0 44.5 47.1 59.8 48.4 55.9
20.0 56.9 61.5 64.5 63 59.6
40.0 73.3 77.9 76.5 69.2 64.6The selected title compounds 5a, 5b, 5f and 5g were sub-
jected to in vitro cytotoxic activity. The results of the MTT as-
say percentage viability, percentage inhibition and IC50 values
are shown in Tables 2–4 and Figs. 1 and 2. Compound 5f has
shown promising cytotoxic activity with percentage viability of
51.3% inhibition of 48.7% at 5.0 lM solution. The IC50 valueFigure 1 Graph of concentration v/s %viability of compound
(5a–5g) by MTT assay.
Figure 2 Graph of concentration v/s %inhibition of compound
(5a–5g) by MTT assay.
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dard cyclophosphamide at 8.7 lM.4. Conclusion
A series of 1-methyl-N-[(substituted-phenylmethylidene)-1
H-benzimidazol-2-amine (4a–4g) were prepared via the forma-
tion of 1-methyl-1H-benzimidazol-2-amine (3), which was
prepared by the cycloaddition of o-phenylenediamine (1) with
cyanogen bromide in the presence of aqueous base followed
by N-methylation with methyl iodide in the presence of anhy-
drous potassium carbonate in dry acetonitrile. Moreover, the
four-membered b-lactam ring was introduced by the cyclo-
addition of 4a–4g and chloroacetyl chloride in the presence
of triethylamine catalyst to give 3-chloro-1-(1-methyl-1H-
benzimidazol-2-yl)-(40-substituted)-phenylazetidin-2-one 5a–5g.
Among the chemicals tested 4a, 4b, 5a, 5b, 5g exhibited good
antibacterial activity and 5f, 5g shown good cytotoxic activity
in vitro. Finally it is conceivable that further derivatization of
such compounds will be of interest with hope to get more selec-
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